Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer

Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer

Background We assessed the safety, efficacy, and pharmacokinetics of the transforming growth factor beta (TGFβ) receptor inhibitor galunisertib co-administered with the anti-programmed death-ligand 1 (PD-L1) antibody durvalumab in recurrent/refractory metastatic pancreatic cancer previously treated...

Full description

Bibliographic Details
Main Authors: Antoine Hollebecque, Rocio Garcia-Carbonero, Do-Youn Oh, Emiliano Calvo, Davide Melisi, Teresa Macarulla, Valeria Merz, Erkut Borazanci, Anna Varghese, Camilla Zecchetto, Yumin Zhao, Ivelina Gueorguieva, Michael Man, Shawn T Estrem, Karim A Benhadji, Emin Avsar, Susan C Guba
Format: Article
Language:English
Published: BMJ Publishing Group 2021-03-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/3/e002068.full

Internet

https://jitc.bmj.com/content/9/3/e002068.full

Similar Items